Premium
No effect of HLA ‐C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T‐cell depletion in patients with hematological malignancies
Author(s) -
Magalhaes Isabelle,
Uhlin Michael,
Schaffer Marie,
Sundin Mikael,
Hauzenberger Dan,
Remberger Mats,
Mattsson Jonas
Publication year - 2017
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13012
Subject(s) - medicine , hematopoietic stem cell transplantation , context (archaeology) , human leukocyte antigen , transplantation , immunology , graft versus host disease , stem cell , oncology , gastroenterology , antigen , biology , paleontology , genetics
HLA ‐C mismatch in unrelated donor's hematopoietic stem cell transplantation ( HSCT ) has been associated with poor patient outcome. However, the impact of HLA ‐C mismatch in the context of HSCT combined with in vivo T‐cell depletion remains unclear. We therefore performed a single‐center, retrospective analysis of the clinical outcome on patients with hematological malignancies treated with allo‐ HSCT , who underwent T‐cell depletion. The majority of the patients (n=276) received a HLA ‐A, HLA ‐B, HLA ‐ DRB 1‐matched graft that were either also HLA ‐C matched (n=260), or patients with the permissive HLA ‐C*03:03/03:04 mismatch (n=16), while the remaining patients (n=95) received a HLA ‐C‐mismatched graft (excluding HLA ‐C*03:03/03:04 mismatches). We did not observe any significant differences between the HLA ‐C‐matched patients (including the permissive HLA ‐C*03:03/03:04 mismatch) and the HLA ‐C‐mismatched patients regarding cumulative proportion surviving, graft failure, relapse‐free survival, relapse, or acute graft‐versus‐host disease. Our data suggest that in the context of high dose T lymphocyte‐depleting agents, HLA ‐C matching is not essential for patients with hematological malignancies.